Compare Citius Pharmaceuticals Inc (CTXR) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Remitly Global Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Remitly Global Inc trades at $24.75 (market cap $4.95B). The key difference: Remitly Global Inc is far larger — about 338.1× Citius Pharmaceuticals Inc's market cap, and Remitly Global Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | RELY | |
|---|---|---|
Market Cap | $14.64M | $4.95B |
Sector | Health | Technology |
52-Week High | $1.82 | $24.28 |
52-Week Low | $0.53 | $12.20 |
Enterprise Value | $10.86M | $4.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
RELY trades at $23.68, down 0.38% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates accelerating revenue growth, reaching $1.64B in 2025 with net income turning positive at $67.93M. Recent expansion includes a UAE banking license and Canadian business launch, supporting the 92% analyst buy rating with a $26.75 consensus target.
Outlook remains positive with projected 2026 revenue of $1.7B and net income of $106M. Key opportunities include market share gains in the $800B remittance space, while risks involve competitive pressure from payment giants and execution challenges in international expansion. The stock offers growth potential but requires monitoring of profitability sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
